Should Counselling Be Required for Patients Using Direct-to-Consumer Pharmacogenetics Tests?
The FDA recently approved a direct-to-consumer drug metabolism test by 23AndMe that may indicate a patient’s response to certain medications. The FDA warned that results from the test should be confirmed with independent pharmacogenetics testing before treatment decisions are made, but many clinicians are worried that consumers will ignore this instruction. Required counselling prior to receiving test results could encourage compliance.
Clinicians are worried that consumers will act on results from direct-to-consumer pharmacogenetics tests without seeking a professional opinion. Are you for or against required counselling for patients using direct-to-consumer pharmacogenetics tests?

Last Answered: Over a month ago